Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. - Pratley RE; Nauck MA; Bailey T; Montanya E; Filetti S; Garber AJ; Thomsen AB; Furber S; Davies M; 1860-LIRA-DPP-4 Study Group; Pratley, Richard E; Nauck, Michael A; et al. (Diabetes Care, 2012)